Table 1.
Population pharmacokinetic parameter estimates of infliximab (base models)
| Hyperparameter | ACT 1 | ACT 2 | P value | ||
|---|---|---|---|---|---|
| Estimate | RSE (%) | Estimate | RSE (%) | ||
| CL (L/day) | 0.378 | 2.9 | 0.388 | 3.0 | 0.529 |
| V1(L) | 3.17 | 2.0 | 2.99 | 3.3 | 0.129 |
| V2(L) | 4.39 | 4.8 | 4.02 | 6.0 | 0.246 |
| Q(L/day) | 6.22 | 8.2 | 10.0 | 8.4 | <0.001 |
| ω2CL | 0.209 | 10.4 | 0.155 | 11.2 | 0.052 |
| ω2V1 | 0.0674 | 14.7 | 0.0938 | 22.8 | 0.254 |
| σ2add | 0.0424 | 6.3 | 0.0407 | 3.7 | 0.582 |
| σ2prop | 0.399 | 3.5 | 0.411 | 3.1 | 0.524 |
CL clearance, V 1 volume of distribution in the central compartment, V 2 volume of distribution in the peripheral compartment, Q intercompartmental clearance, RSE relative standard error.